Enigmata Cipher runs AI directly on encrypted data at production speed, turning the world’s locked-away data into fuel for AI

NASHVILLE, Tenn., Sept. 10, 2026 — Enigmata, Inc. emerged from stealth today with $6.5 million in seed funding led by Blockchange Ventures to commercialize Enigmata Cipher™, a patent-pending cryptographic technology that lets artificial intelligence train, search, and analyze data while it remains encrypted.

Cipher is designed for AI workflows where sensitive data would otherwise be exposed, including model training on proprietary datasets, enterprise use of third-party AI systems, semantic search, analytics, and agentic applications.

The world’s most valuable data is often the hardest to use. Clinical records that could improve cancer detection, transaction histories that could help stop fraud, and archives that could train more capable models are locked inside institutions that cannot risk exposing them. Cipher gives organizations a way to put that data to work in AI while keeping it protected.

Cryptographers have pursued computation on encrypted data for decades. Existing approaches have historically forced trade-offs among flexibility, performance, and security. Enigmata Cipher takes a different approach designed around the speed, cost, and flexibility modern AI workloads require.

Cipher transforms records, documents, and datasets into an encrypted form that AI, analytics, and search tools can use on existing enterprise hardware. Because the technology simultaneously structures and encrypts data, it can also improve performance. In Enigmata’s internal benchmarks, models trained on Cipher-protected data matched the accuracy of models trained on raw data while completing training 8% to 10% faster. Cipher also supports targeted removal of individual records without retraining a model from scratch, which can help organizations respond to data-deletion requests.

“Every era of computing has forced a choice between using data and protecting it. Enigmata Cipher ends that trade-off,” said Scott Searle, co-founder and CEO of Enigmata. “The world’s most valuable data no longer has to stay locked away to stay protected. When hospitals, banks, and publishers can safely use their most sensitive assets in AI, we stop asking what AI is allowed to know and start asking what it can safely discover, prevent, and create.”

Enigmata’s long-term vision is to extend Cipher into infrastructure for secure data licensing. Institutions could make encrypted datasets available for AI training under enforceable usage terms while retaining control of the underlying assets. As copyright disputes reshape how AI companies access training data, Cipher could give data owners a way to participate directly in the value their data creates.

“Privacy is the next great frontier for AI,” said Matt Immerso, general partner at Blockchange Ventures. “Every advance in hardware and models only matters if customers are comfortable putting their most sensitive data into AI. Enigmata built encryption for exactly that, from the ground up. We believe Enigmata Cipher will become a core pillar of the AI data economy, defining how sensitive data is used, licensed, and monetized in the AI era.”

Enigmata Cipher is now available to selected enterprise design partners. Organizations can request access at enigmata.xyz.

ABOUT ENIGMATA

Enigmata, Inc. is trust infrastructure for the AI data economy. The company’s patent-pending core technology, Enigmata Cipher, lets organizations use sensitive data with AI without exposing plaintext to models or processing infrastructure, enabling AI and analytics to operate directly on encrypted data at production speed. Founded in 2024, Enigmata is built for banks, insurers, health systems, life sciences organizations, publishers, data providers, and model owners with valuable data they cannot safely expose but need to use in AI workflows. Learn more at enigmata.xyz.

ABOUT BLOCKCHANGE VENTURES

Blockchange Ventures is a venture capital firm founded in 2017 to capitalize on the investment opportunity created by blockchain technology. The firm manages approximately $900 million in assets and has returned nearly $1 billion to investors. Blockchange partners with visionary, entrepreneurial founders building large, enduring companies at the intersection of blockchain’s technological promise and commercial reality.

SOURCE Enigmata

SIF XII builds on Pinegrove’s 26-year track record of top-quartile performance, providing institutional investors with concentrated exposure to leading venture managers and the world’s most innovative private technology companies

SAN FRANCISCO, Sept. 10, 2026 — Pinegrove Venture Partners (“Pinegrove”) today announced the final closing of Strategic Investors Fund XII (“SIF XII”), raising $1.5 billion across its Early and Scale strategies. SIF XII was significantly oversubscribed, with investor demand far exceeding the strategy’s fundraising target.

For over 26 years, the SIF program has provided institutional investors with concentrated exposure to a select group of leading and emerging venture managers and, through those managers, the innovative companies they back. SIF XII continues that approach through two complementary strategies: SIF XII-Early, which invests with early-stage managers, and SIF XII-Scale, which invests with expansion-stage managers and selective co-investments alongside leading GPs. Together, the strategies enable investors to build exposure across the venture lifecycle.

“Venture capital rewards patience, conviction and trusted relationships,” said Aaron Gershenberg, Managing Partner of Pinegrove Venture Partners. “Pinegrove has worked to provide institutional investors with differentiated access to the managers, companies and opportunities shaping the innovation economy. SIF XII reflects the continued confidence of our partners in that approach and in our ability to create value through every phase of the venture cycle.”

Pinegrove’s differentiated approach extends beyond manager selection. The firm’s long-standing partnerships create a durable information advantage and position Pinegrove to identify opportunities that are often unavailable through conventional venture fund primary structures. This includes bespoke co-investments, tailored portfolio solutions and strategic capital opportunities developed in collaboration with venture managers, founders and limited partners.

“Pinegrove has established a leading venture platform through decades of trusted relationships across the innovation ecosystem,” said Anuj Ranjan, CEO of Brookfield Private Equity. “Over the past several years, Aaron Gershenberg, Sulu Mamdani, Thorben Hett, and the broader team have continued to enhance that platform, building an exceptional portfolio with SIF XII, while deepening the firm’s position as a trusted partner to leading venture managers and institutional investors. Their continued focus on partnership and disciplined execution has further strengthened Pinegrove’s position within the venture ecosystem, and we believe the firm is exceptionally well positioned for the years ahead.”

Pinegrove’s objective is not merely to provide venture exposure; it is to serve as a strategic partner to institutional investors navigating a complex and increasingly specialized private-markets landscape. The firm works with its limited partners to build portfolios that reflect their individual objectives, pacing needs and risk parameters.

“We could not be more excited to anchor Pinegrove SIF XII,” said John Bradley, Head of Private Equity for the Florida State Board of Administration. “Pinegrove is one of our most important and successful partnerships, helping us access the innovation economy.”

SIF XII is investing across a three-year vintage during a period of accelerating innovation across artificial intelligence, infrastructure, enterprise software, healthcare, life sciences and defense. Through its underlying venture managers and co-investment program, the fund has already provided exposure to leading private technology companies while continuing to invest in the next generation of category-defining businesses as they emerge. With SIF XII now closed, Pinegrove will continue deploying capital across its Early and Scale strategies while partnering with leading venture managers and institutional investors worldwide.

About Pinegrove
Pinegrove operates an integrated investment platform with over $15 billion in assets under management across venture fund primaries and co-investments (Pinegrove Strategic Partners), venture debt and private credit (Pinegrove Credit Partners), and venture and growth secondaries (Pinegrove Opportunity Partners). Backed by HRTG Partners and Brookfield Asset Management, Pinegrove combines complementary investment capabilities to serve founders, companies, venture managers and institutional investors with creative and tailored capital solutions

SOURCE Pinegrove Venture Partners

LOS ANGELES, Sept. 10, 2026 — Liberty Hill Foundation today announced the 17 members of its 2026 Fund for Change cohort, a countywide group of grassroots organizations confronting injustice, strengthening their communities, and expanding what is possible across Los Angeles County.
 
For 50 years, Liberty Hill has invested in the people and organizations building grassroots power across Los Angeles, often providing early and flexible funding at times when community organizations have had the least access to traditional philanthropy. Many members of the 2026 cohort are emerging or smaller organizations that bring trusted relationships, cultural insight, lived experience, and community-shaped solutions to the issues Angelenos are facing.

At the heart of the Fund for Change is the Community Funding Board (CFB), an innovative participatory grantmaking model grounded in the belief that those closest to community issues and solutions should help shape funding decisions. Bringing together movement leaders, donors, and philanthropic partners, the CFB is a core part of the Foundation’s participatory philanthropy model. It creates a space where community expertise, philanthropic investment, and shared learning come together to strengthen movement building across Los Angeles. The 2026 Fund for Change cohort was selected through the Community Funding Board.

Several organizations in this year’s cohort are working to advance issues at the core of Liberty Hill’s Agenda for a Just Future, which includes ending youth incarceration as we know it and investing in a comprehensive youth development system, addressing the housing crisis and expanding tenants’ rights, and eliminating toxic neighborhood oil drilling.

“What sets Fund for Change apart is not only the funding itself, but the collective wisdom behind it,’ said Shane Murphy Goldsmith, President and CEO of Liberty Hill Foundation. “For 50 years, Liberty Hill has invested early in organizations that have gone on to become essential pillars of Los Angeles’ movement ecosystem. These organizations carry that commitment forward and remind us that the future we’re working toward is already taking root.”

The work of the new cohort reflects Liberty Hill’s six interconnected priority areas—Youth & Transformative Justice; LGBTQ & Gender Justice; Environmental & Climate Justice; Economic & Housing Justice; Electoral Power Building; and Healing Justice—with racial justice embedded across all of them.

“These organizations are not waiting for permission to build the future Los Angeles deserves. They are already doing the work — in neighborhoods, with families, with young people, with tenants, with workers, and with communities that know better than anyone both the harm they are up against and the solutions they are building,” said Manal J. Aboelata, Chief Program Officer of Liberty Hill Foundation. “Through Fund for Change and its Community Funding Board, Liberty Hill honors that wisdom, centers people closest to the work in accountable decision-making, and moves resources toward the grassroots leadership our region so deeply needs.”

Reflecting on the experience, Community Funding Board member and Liberty Hill donor advised fund holder Allison Thomas shared, “It’s easy to be optimistic when you’ve gone through this process. People are doing incredible work across the county, and they’re people that are often directly impacted by the issues or deeply connected to the communities they serve. They’re selfless, they’re passionate, and committed—it’s very inspiring.”
 
From the Antelope Valley to Long Beach and from unincorporated South Los Angeles to the San Fernando Valley, the 2026 Fund for Change cohort reflects the breadth and local leadership of Los Angeles’ movement for justice. Thanks to the generous support of funding partners and donors, Liberty Hill is investing $1.9 million in three-year general operating grants to support the 2026 Fund for Change cohort.

As Liberty Hill celebrates 50 Years of Solidarity & Progress by continuing to invest in community-rooted leadership, the Foundation and its partners are looking toward the future of Los Angeles in the next 50 years and beginning to plant the seeds of a more just future today.
 
Meet the 2026 Fund for Change cohort at libhill.co/ffc.

About Liberty Hill Foundation

Liberty Hill Foundation is a laboratory for social change philanthropy. We leverage the power of community organizers, donor activists, and allies to advance social justice through strategic investment in grants, leadership training, and campaigns. We envision a society in which all people have a powerful voice, including those currently shut out of our democracy, people cut off from opportunities because of their skin color, gender or sexual orientation, where they live, or where they were born. We will not rest until society provides justice and equality for all. 

SOURCE Liberty Hill Foundation

The investment will support Tom Beckbe’s vision for growth and conservation

BIRMINGHAM, Ala., Sept. 10, 2026 — Tom Beckbe, the Birmingham-based maker of classic American outdoor apparel and gear, today announced it has received a minority investment from Cox Outdoors.

“We built Tom Beckbe with a focus on great products, great customer service, and support for conservation. Our new partnership with Cox will allow us to double down on those core values,” said Radcliff Menge, co-founder of Tom Beckbe. “Cox has been doing business the same way for generations, putting people first and thinking in decades instead of quarters. And that’s exactly the partner we wanted.”

Founded in 2015 by Radcliff and Mary Menge, Tom Beckbe began with the simple idea for a better hunting jacket. The brand has since grown to offer a full line of apparel and gear for the field and every day, available online and through a growing network of owned and partner stores. Tom Beckbe’s newest retail location, in Atlanta’s Buckhead neighborhood, will open this September.

“We’re very excited to be in business with Tom Beckbe. Radcliff and Mary have built a great business on family values and a conservation ethic that resonates with Cox’s values,” said Alex Taylor, chairman and CEO of Cox Enterprises. “I love their stuff and look forward to building something great together.”

Cox Outdoors is Cox Enterprises’ newest division, focused on partnering with leading outdoor consumer brands to drive conservation and generational growth. Cox’s partnership with Tom Beckbe will support the Menges’ growth vision for the business, from new retail stores to continued product development and ongoing work with conservation organizations such as Ducks Unlimited and Bonefish Tarpon Trust.

Tom Beckbe will remain independently run by its founders, with the same team, the same values, and the same commitment to craft that have defined the brand since 2015.

SOURCE Tom Beckbe

Kelly was designed by 25-year veterans of Two Sigma, BlackRock, Axioma and Barra, and computes every answer on the analytics engine trusted by managers overseeing more than $7 trillion in assets.

NEW YORK, Sept. 10, 2026 — Omega Point, the portfolio intelligence platform – trusted by investment managers globally for over a decade, today announced the launch of Kelly, its AI agent for investment intelligence. Kelly is designed & built by market veterans, who have spent their careers getting it right. Working with Kelly feels like having a seasoned expert at your side, sharpening your thinking with every question. Ask it to dig in like an analyst, think through construction like a PM, challenge your assumptions like a risk manager, or evaluate a manager the way an allocator would. Conversations with Kelly result in bespoke answers and dashboards that reflect the manager’s approach and strategy.

To be a top-tier firm today, you have to perfect all aspects of the investment process simultaneously: deciding which names deserve the work, sizing positions, understanding the scenarios that aren’t priced in, hedging deliberately, and making all of it repeat across the firm. That’s always been difficult, because it takes deep expertise across every one of those specialties, and market veterans are the scarcest resource in the industry. When an answer costs a day of a veteran’s attention, the question often doesn’t get asked.

“We built Kelly so there is no more waiting for an expert,” said Omer Cedar, CEO of Omega Point. “A firm’s IP is its greatest asset, and Kelly puts a market veteran at every desk to sharpen it. The more your team works with it, the more it reflects how your team actually thinks.”

The launch reflects a strategic choice. Most firms whose clients pay for their expertise guard it closely. Omega Point is doing the opposite: packaging what its market veterans know into an agent every customer can work with, backed by prebuilt workflows that span the investment process. Kelly turns that expertise into an edge every person can sharpen for themselves, one question at a time. 

Kelly is an evolution of the platform Omega Point has built over thirteen years, not a separate product. Every number Kelly returns is computed on Omega Point’s Investment Intelligence Engine, the same deterministic calculation engine that has been trusted by the world’s largest investors for over a decade; every figure is traced to source; and governance is by design, with Kelly operating strictly within each user’s existing access privileges. Kelly is available to every firm and is enabled only with the firm’s explicit permission.

“Firms that beta-tested Kelly over the summer were asking questions they never had time to ask before, and building their own analytics around the answers,” Cedar said. “That is the outcome we designed for. Every person in the firm now works with that experience at their side, constantly sharpening their edge.”

Firms interested in Kelly can visit omegapoint.ai. Read the full announcement here.

Omega Point

Omega Point is the investment intelligence platform built by investors, for investors. Founded in 2013, it distills the experience of market veterans into analytics that run inside the front-office workflows of hedge funds, asset managers, pensions and sovereign investors overseeing more than $7 trillion in assets. Kelly, its AI agent, turns questions into bespoke analysis that sharpens each firm’s edge, computed on its platform, traced to source and governed by design. Omega Point is headquartered in New York and San Francisco. Visit omegapoint.ai.

Media Contact
Joel Coverdale
+44(0)7383 819862
[email protected]

SOURCE Omega Point

Arnold joins a leadership, governance, and advisory team with experience spanning wealth management, technology, compliance, investment strategy, entrepreneurship, and global leadership.

NEW YORK, Sept. 10, 2026 — Stirlingshire Investments today announced the appointment of Dan Arnold, former President and Chief Executive Officer of LPL Financial, as Executive Chairman of the Board. Arnold will serve in an active leadership role, working directly with Founder and CEO Steven Woods and the Company’s executive team to provide strategic oversight, with a focus on advisor recruitment, operational excellence, strategic partnerships, and the continued scaling of Stirlingshire’s growth initiatives.

Arnold brings decades of wealth management experience. During his tenure at LPL Financial, he helped guide the growth of one of the largest independent wealth management platforms in the United States and developed longstanding relationships with advisors, enterprise leaders, branch organizations, and recruiting professionals across the industry.

“Dan’s reputation, leadership experience, and relationships are unparalleled in our industry,” said Woods. “He has spent his career helping advisors build successful businesses, and his decision to join Stirlingshire is a powerful validation of both our platform and our vision. Over the past several months, getting to know Dan and working with him to shape Stirlingshire’s roadmap has been an incredible experience. Dan had many options for what he could do next, and we are thrilled he chose Stirlingshire as one of them.”

Leadership Built Across the Full Wealth Management Enterprise

Arnold joins a multidisciplinary team supporting the continued development and responsible growth of Stirlingshire and Stirling One, the Company’s AI-native Wealth Management Operating Platform. Together, the Company’s executive leadership, Board of Directors, and Advisory Board bring experience spanning financial services, investment management, compliance, technology, governance, entrepreneurship, law, and public policy.

Founder and Chief Executive Officer Steven Woods has more than 15 years of experience spanning portfolio management, finance and client service, and has completed executive programs at Harvard Business School and the University of Oxford. Chief Technology Officer Constantine Gavalas, formerly Global Head of Technology Operations and CIO, Global Delivery at State Street Corporation and Director of Technology Operations at London Stock Exchange Group, leads the architecture and development of Stirlingshire’s integrated operating platform. Chief Compliance Officer Candice Gilman brings more than 18 years of financial services compliance experience and previously served as Chief Compliance Officer of SoFi Wealth, where she developed the compliance program for its online, multibillion-dollar registered investment adviser. Chief Market Strategist David Lundgren is the former Director of Technical Research at Wellington Management, an experienced portfolio manager and a board member of the CMT Association.

In addition to Arnold and Woods, Stirlingshire’s Board includes Scott Friedman and Ash Kalb. Friedman brings more than 25 years of experience and was a founding team member at Robinhood, where he served as President and Chief Compliance Officer of Robinhood Financial and Robinhood Securities. Kalb is Co-Founder and President of Fulcra Dynamics and a Co-Founder of Katalys. He previously co-founded White Ops, now HUMAN Security, which grew from an early-stage startup into a global cybersecurity platform that currently verifies more than 20 trillion digital interactions each week across approximately three billion devices.

Stirlingshire’s Advisory Board includes Sir Conor Burns and Dr. Andrew White. Sir Conor brings experience in financial services, regulation, public policy, and trade, having served for 14 years in the British House of Commons and as a United Kingdom Trade Envoy. Dr. White is the former Director of Executive Education at the University of Oxford’s Saïd Business School and former Director of the Oxford Advanced Management and Leadership Programme.

“The opportunity ahead requires more than technology alone,” Woods said. “It requires experienced leadership, disciplined governance, regulatory depth, and people who understand how financial advisors build and operate their businesses. Dan’s appointment strengthens an already exceptional group, and together this team gives Stirlingshire the perspective and capability to execute on our long-term strategy.”

A Platform Designed Around Advisors and Their Clients

Stirlingshire’s vertically integrated operating platform, Stirling One, brings core wealth management functions into one connected environment, including onboarding, portfolio management, trading, rebalancing, tax optimization, compliance, reporting, CRM, communications, and AI-powered advisor tools. Its advisor model includes a 100% payout and zero platform expenses.

About Stirlingshire Investments

Stirlingshire Investments is a next-generation wealth management firm built around the belief that the industry can be better for both clients and advisors. Through its proprietary, vertically integrated technology platform, Stirlingshire delivers a modern wealth management experience while offering advisors a true 100% payout model with zero platform expenses. Unlike traditional firms that rely on disconnected third-party vendors and retain a portion of advisor revenue, Stirlingshire has built a fully integrated ecosystem that brings together client onboarding, portfolio management, trading, rebalancing, compliance automation, reporting, AI-powered advisor tools, marketing, and client communications through a single login and turnkey platform. With a growing network of advisors, strategic partnerships, and a commitment to innovation, Stirlingshire is redefining how wealth management is delivered under its guiding principle: Better for Clients, Better for Advisors™.

For more information, visit www.stirlingshire.com.

Media Inquiries:

Nicole Cox

Chief Marketing Officer, Stirlingshire Investments

[email protected]

647-500-2763

SOURCE Stirlingshire

• Former Eli Lilly Oncology CSO, co-inventor of the first CAR-T product
• Kos announced the third closing of its inaugural venture fund with $123 million in June 2026

NEW YORK and ATHENS, Greece, Sept. 10, 2026 — Kos Biotechnology Partners, a global life sciences investment firm, today announced the appointment of renowned immuno-oncology leader Michael Kalos, PhD, as Venture Partner. Dr. Kalos brings decades of biopharmaceutical executive leadership, drug discovery, translational medicine, and venture creation experience to the firm.

In his new role, Dr. Kalos will support Kos in identifying transformative development-stage and platform opportunities, advising portfolio companies, and driving strategy within the immuno-oncology and cell therapy domains.

A Legacy of Leadership in Immuno-Oncology

Dr. Kalos is a globally recognized expert in immuno-oncology, cancer immunotherapy, and cellular therapies. Throughout his distinguished career, he has held key executive positions at leading global pharmaceutical companies, including Eli Lilly and Janssen, where he played pivotal roles in advancing novel modalities from target discovery through clinical development.

At Janssen Oncology (Johnson & Johnson), Dr. Kalos served as Vice President and Head of Immuno-Oncology and Cell Therapies, where he led strategy and execution for Janssen’s robust immuno-oncology portfolio, driving the advancement of innovative cellular therapies and multi-specific antibodies into the clinic.

Prior to Janssen, Michael served as Chief Scientific Officer of Immuno-Oncology at Eli Lilly and Company, where he directed Lilly’s scientific vision, research programs, and external innovation pipeline in immuno-oncology, establishing key academic and industry collaborations to accelerate breakthrough oncology platforms.

Prior to his career in the biopharma industry, Dr. Kalos spent 10 years in academia, including the University of Pennsylvania where he built and directed the Translational and Correlative Studies Laboratory that was instrumental in the early development of landmark CAR-T cell therapies. During his tenure at the University of Pennsylvania, Dr. Kalos played a key role in the clinical development and is a co-inventor of CTL019, the CAR T-cell therapy later licensed to Novartis and approved as Kymriah, the first FDA-approved CAR T-cell therapy.

Dr. Kalos holds a PhD in Molecular Genetics and Microbiology from the University of Minnesota and completed his post-doctoral training at the Fred Hutchinson Cancer Research Center. He has authored over 100 peer-reviewed scientific publications and patents in the fields of oncology, immunology, and cell and gene therapy.

Executive Commentary

“I am truly excited to join Kos Biotechnology Partners at a time of unprecedented opportunity in the life sciences landscape,” said Dr. Kalos. “Kos’s nimble, cross-border investment model and deep commitment to foundational science provide an extraordinary platform to translate cutting-edge immuno-oncology and therapeutic modalities into tangible medicines for patients worldwide. I look forward to working alongside Simos, Alex, and the entire Kos team.”

“Michael is one of the true pioneers in cell therapy and immuno-oncology, with an unmatched track record of driving foundational scientific breakthroughs into clinical pipelines at top-tier organizations like Lilly and Janssen,” said Dr. Simos Simeonidis, Co-Founder and Managing Partner of Kos Biotechnology Partners. “I have known Michael personally and professionally for over a decade and I couldn’t be more excited about having him on our team. I am confident that his deep scientific insight and operational experience will be invaluable to Kos as we continue to build and back high-impact biotech platforms.”

“Adding a Venture Partner of Michael’s caliber reinforces Kos’s mission to align world-class domain expertise with transformative capital”, added Alex Tzoukas, Co-Founder and Managing Partner. “His specialized perspective in complex biological modalities directly supports our investment strategy and portfolio creation.”

About Kos Biotechnology Partners

Kos Biotechnology Partners is a global life sciences investment firm based in New York and Athens, Greece, managing a $123 million fund that targets advancements in biotech, pharma services, and healthcare technology, with investments ranging from company formation to later stages of development.

Contact:

Kos Biotechnology Partners

Email: [email protected]

Website: www.kosbp.com

SOURCE Kos Biotechnology Partners

Federal funding backs engineering to advance the wireless and radio-frequency systems for the wearable toward manufacturing at scale, in partnership with the University of Arizona

TUCSON, Ariz., Sept. 10, 2026 — Senphonix, Inc., a medical-technology startup developing SleeveSense™, a wearable that will continuously monitor patients’ vital signs over days, weeks, or months, today announced it has received a Small Business Technology Transfer (STTR) Phase I award from the U.S. National Science Foundation (NSF) through America’s Seed Fund. The award supports engineering to strengthen the patent-pending device’s wireless and radio-frequency systems and to move it from prototype toward a manufacturable product at scale, in partnership with the University of Arizona.

In hospitals and after discharge, vital signs are typically captured as periodic spot checks, and nurses can spend up to and sometimes in excess of 20 percent of every shift measuring vitals manually. SleeveSense is designed as an automated, comfortable, long-term sleeve worn by the patient both during the hospital visit and once discharged. The device will stream multiple vital signs continuously, with the goals of removing manual processes, surfacing signs of patient deterioration earlier and giving clinicians a fuller picture after discharge.

“This award is significant validation of the critical needs SleeveSense will address,” said Mike Haldane, Co-Founder and Co-CEO of Senphonix. “Continuous, comfortable, long-term monitoring can change how patient vitals are tracked both in the hospital and at home. NSF’s support lets us further engineer the technology as we prepare to go to market in 2027.”

Under the STTR Phase I award, Senphonix and the University of Arizona will focus on the device’s wireless and radio-frequency performance in real hospital environments, including its antenna and power systems, and the advanced engineering required to move the sleeve toward what is expected to be significant manufacturing volumes.

The STTR award builds on earlier support from the State of Arizona, where matching grant funding from the Arizona Commerce Authority, through the WearTech Applied Research Center, backed Senphonix’s early design work. “Arizona has built an ecosystem where promising medical technology companies can find the support they need to grow, and Senphonix is a strong example of that pipeline at work,” said Kathleen Lee, Director of Applied Research Programs for the Partnership for Economic Innovation. “That funding gave the team the runway to move from concept to working prototype, and now, with a federal NSF award strengthening the effort, Senphonix shows what becomes possible when the right support is in place at the right time.” The federal award, together with founder and private funding, continues the company’s Arizona-based research and its partnership with the University of Arizona.

The underlying clinical need has been affirmed by the people closest to it: in a national survey of practicing nurses, 98 percent (n=402) said they would support SleeveSense if it saves some of the time associated with taking manual vital signs. In a separate study, 94 percent of CFOs (n=457) indicated an intent to support adoption, especially if it can drive nursing efficiency, better patient outcomes, and avoidance of readmissions. The CFO study also identified an interest in remote patient monitoring, with SleeveSense serving as the platform.

“Translating advanced wearable sensing from the lab into a device that performs reliably in a real clinical setting is a significant engineering challenge, and it is exactly where academic research and a focused startup accomplish more together than apart,” said Dr. Philipp Gutruf, Associate Professor in the Department of Biomedical Engineering at the University of Arizona. “We are excited to bring our expertise in biosymbiotic electronics to the SleeveSense platform.”

Senphonix intends to pursue U.S. Food and Drug Administration (FDA) clearance for SleeveSense in early to mid-2027, once clinical testing is completed. Clinical testing is expected to begin in late 2026 or early 2027.

About Senphonix

Senphonix, Inc., is a medical-technology company developing SleeveSense, a wearable platform for continuous, comfortable, long-term monitoring of vital signs in clinical and home settings. The platform is designed to seamlessly support inpatient, outpatient, and at-home use, which is expected to be both cost-effective for the hospital and a high-value option for ensuring a patient’s well-being once discharged. The company is a C-Corp based in Delaware, with offices in Arizona and Minnesota. Learn more at www.senphonix.com. 

About America’s Seed Fund powered by NSF

America’s Seed Fund, powered by the SBIR/STTR program of the U.S. National Science Foundation, provides non-dilutive funding to startups and small businesses to translate research into products and services with strong commercial potential and societal benefit.

This material is based upon work supported by the U.S. National Science Foundation under Award No. 2537968. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the National Science Foundation.

SleeveSense is an investigational device. It is not currently cleared or approved by the U.S. Food and Drug Administration and is not available for sale. This release contains forward-looking statements about product development, regulatory plans, and future performance that involve risks and uncertainties; actual results may differ.

Market research was administered by MarketWise Advising, LLC, via national surveys conducted in 2025 and 2026 for Senphonix.

Media Contact

Michelle Gjerde, PR Specialist
Senphonix, Inc.

[email protected] | 605-303-1934 

Product photos available upon request.

SOURCE Senphonix, Inc.

NEW YORK, Sept. 10, 2026 — Maywood, the first finance-compliant proactive AI built for investment banking, accounting, corporate banking, and the broader financial services industry, today announced it has partnered with PitchBook, the leading private capital market intelligence platform, to integrate its data into Maywood’s AI harness. The integration enables Maywood’s agents to leverage the breadth of PitchBook’s data to proactively track private companies, identify key signals, and help teams make more informed deal decisions.

The integration enables Maverick, Maywood’s proactive AI agent, to access and deliver best-in-class and trusted private company data covering 30+ key firmographic details through the PitchBook Essential Connector. Maverick’s suggestions and actions for private companies are now tied to the most trusted private data source, giving senior dealmakers assurance and conviction in taking action. PitchBook data will be delivered directly to Maverick users through email, Teams, and the platform.

“Senior dealmakers can now take the same level of care and fidelity they provide to their top prospect and apply that at scale to the rest of their network,” said Kent Goodman, Chief Operating Officer of Maywood. “This flips the paradigm of what was previously possible, and it means better relationships, better service, and more advisory across the industry. Senior dealmakers now know that their decisions are grounded in PitchBook’s trusted data, so managing directors and partners are in front of the right person at exactly the right time.”

Maverick is purpose-built for the senior professionals who drive revenue across investment banking, private equity, commercial banking, wealth management, auditing, and business development. It embeds compliant AI into the systems they already use and is built to FINRA and SEC requirements from day one, with human approval at every external boundary.

About Maywood
Maywood is a leader in proactive AI for finance, spanning investment banking, commercial banking, lending, private credit, private equity, wealth management, auditing, and business development. Its agent Maverick is the first finance-compliant proactive AI that runs 24/7, purpose-built for managing directors and partners. Every senior professional carries hundreds of relationships and dozens of live deals, and today’s AI waits to be prompted, making the human the bottleneck. Maywood inverts that: it works in the background across your network and your deal book, surfacing moves, drafting replies, and pushing process forward. For more information, visit www.maywoodai.com and follow us on LinkedIn.

Media Contact
[email protected]

SOURCE Maywood